Clear Creek Financial Management LLC Buys New Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Clear Creek Financial Management LLC bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 5,638 shares of the company’s stock, valued at approximately $352,000.

A number of other large investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. Public Sector Pension Investment Board acquired a new position in shares of TransMedics Group in the third quarter worth $11,079,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after acquiring an additional 64,872 shares during the period. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its holdings in TransMedics Group by 657.6% in the third quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock valued at $10,111,000 after purchasing an additional 55,900 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Up 0.9 %

TMDX opened at $67.55 on Monday. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $2.27 billion, a P/E ratio of 71.86 and a beta of 2.12. The business’s 50-day simple moving average is $67.28 and its 200-day simple moving average is $111.99.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TMDX shares. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Canaccord Genuity Group lowered their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.